• Leave Judgement at the Door

    (A report back from lived experience speakers)

    The rapid developments in Hepatitis C management since direct acting antiviral therapy became available on the pharmaceutical benefits scheme in March 2016 has been nothing short of amazing. Now with the advent of pan genotypic regimes and comparative treatment success regardless of the presence of cirrhosis, Australia is a privileged and unique position to ensure no one is left behind in its pursuit of Hepatitis C eradication by 2030. Despite this, achieving this target remains ambitious given the stigma associated with a Hepatitis C diagnosis.